The laboratory of clinical virology in monitoring patients undergoing monoclonal antibody therapy

Clinical Microbiology and Infection

Volumn 17, Issue 12, 2011, Pages 1781-1785

  Cavallo, R ^a,b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Hepatitis viruses; Herpesviruses; Monitoring; Monoclonal antibodies; Polyomaviruses

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; HEPATITIS B VACCINE; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB;

ANKYLOSING SPONDYLITIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC LYMPHOCYTIV LEUKEMIA; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENTERITIS; EPSTEIN BARR VIRUS INFECTION; GRAFT VERSUS HOST REACTION; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION RISK; JC VIRUS INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; PAPILLOMAVIRUS INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; VARICELLA ZOSTER VIRUS; VIROLOGY; VIRUS INFECTION; VIRUS REACTIVATION; VIRUS REPLICATION;

POLYOMAVIRUS;

EID: 81255150498     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03678.x     Document Type: Review

References (33)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
2. Rigal E, Gateault P, Lebranchu Y, Hoarau C. Les complications infectieuses liées à l'utilisation des anticorps monoclonaux chez home. Med Sci (Paris) 2009; 25: 1135-1140.
3. Cheung WW, Tse E, Leung AYH, Yuen K-Y, Kwong Y-L. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am J Hematol 2007; 82: 108-111.
4. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006; 7: 125-130.
5. Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307-1312.
6. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69.
7. Tsutsumi Y, Kawamura T, Saitoh S et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-629.
8. Niscola P, Del Principe MI, Maurillo L et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005; 19: 1840-1841.
9. Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 1053-1056.
10. Tsutsumi Y, Ogasawara R, Kamihara Y et al. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010; 2010: 182067.
11. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
12. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61: 35-47.
13. Dubois V, Moret H, Lafon ME et al. Prevalence of JC virus viremia in HIV-infected patients with or without neurological disorders: a prospective study. J Neurovirol 1998; 4: 539-544.
14. Zylberg H, Rimaniol AC, Pol S et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999; 30: 185-191.
15. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-322.
16. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000; 223: 241-257.
17. Domm S, Cinatl J, Mrowitz U. The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228.
18. Ostuni P, Botsions C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 686-687.
19. Michel M, Duvoux C, Hezode C et al. Fulminant hepatitis after inflizimab in a patient with hepatitis B virus treated for adult onset Still's disease. J Rheumatol 2003; 30: 1624-1625.
20. Millonig G, Kern M, Ludwiczek O et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974-976.
21. Montiel PM, Solis JA, Chirinos JA et al. Hepatitis B virus reactivation during therapy with etarecept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718-720.
22. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002; 14: 1393-1395.
23. Haerter G, Manfras BJ, Jong-Hesse Y et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004; 39: e88-e94.
24. Sari I, Birlik M, Gonen C et al. Cytomegalovirus colitis in a patient with Behçet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008; 14: 2912-2914.
25. Mizuta M, Schuster MG. Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2005; 40: 1071-1072.
26. Kohara MM, Blum RN. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2006; 42: 733-734.
27. Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 2503-2504.
28. Reijasse D, Le Pendeven C, Cosnes J et al. Epstein-Barr virus load in Crohn's diseases: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004; 10: 85-90.
29. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 20-34.
30. Cepeda EJ, Williams FM, Ishimori MI et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67: 710-712.
31. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009; 3: 47-91.
32. Furst DE, Keystone EC, Kirkham B et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67: iii2-iii25.
33. Carpenter B, Haque T, Dimopoulou M et al. Incidence and dynamics of Epstein-Barr reactivation after alentuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation 2010; 90: 564-570.